Innate and cellular immune response to the Ebola vaccine Ad26.ZEBOV, MVA-BN-Filo: an ancillary study of the EBL2001 phase II trial.

Christine LacabaratzMélany DurandAurélie WiedemannEmile FoucatMathieu SurénaudCorinne KriefLydia GuillaumatCynthia RobinsonKerstin LuhnViki BockstalRodolphe ThiébautLaura Richert Yves Lévy

Published in: The Journal of infectious diseases (2024)

This study provides unique insights into the in vivo contribution of proliferation/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency.

Keyphrases

immune response
clinical trial
inflammatory response
open label
study protocol